Early results from a Phase II study demonstrate that Bristol-Myers Squibb’s experimental drug has unrivaled potency against the Hepatitis C virus.
Bristol compound potent against hepatitis C
(Reuters) – An experimental Bristol-Myers Squibb compound called BMS-790052 is proving to be the most potent yet at treating hepatitis C, an infection poorly treated with existing drugs, company researchers said on Wednesday.
An early, phase I safety study of the compound found it was highly effective at blocking the protein NS5A, a new target that might provide one more weapon against a virus that can quickly develop resistance.
Continue reading this entire article:
http://www.reuters.com/article/idUSTRE63K5QB20100421